Regorafenib (Stivarga) in all diseases

From - A Hematology Oncology Wiki
Jump to: navigation, search

Colon cancer

GIST (Gastrointestinal Stromal Tumor)

Hepatocellular carcinoma

Source: Regorafenib (Stivarga) for hepatocellular carcinoma

back to top


Study Evidence Comparator Comparative Efficacy
Bruix et al. 2016 (RESORCE) Phase III Placebo Superior OS


28-day cycles


  1. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36. link to original article contains protocol PubMed